Related references
Note: Only part of the references are listed.Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses
Benjamin Uttenthal et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Clinical evaluation of systemic and local immune responses in cancer: time for integration
Dmitriy W. Gutkin et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors
Jaikumar Duraiswamy et al.
CANCER RESEARCH (2013)
A Dendritic Cell Vaccine Pulsed with Autologous Hypochlorous Acid-Oxidized Ovarian Cancer Lysate Primes Effective Broad Antitumor Immunity: From Bench to Bedside
Cheryl Lai-Lai Chiang et al.
CLINICAL CANCER RESEARCH (2013)
WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial
Takashi Miyatake et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2013)
IRX-2, a Novel Immunotherapeutic, Enhances Functions of Human Dendritic Cells
Bastian Schilling et al.
PLOS ONE (2013)
Dendritic cell-targeted approaches to modulate immune dysfunction in the tumor microenvironment
Anne Gallois et al.
FRONTIERS IN IMMUNOLOGY (2013)
CD137L-stimulated dendritic cells are more potent than conventional dendritic cells at eliciting cytotoxic T-cell responses
Zulkarnain Harfuddin et al.
ONCOIMMUNOLOGY (2013)
Endometrial cancer
Vivek Arora et al.
BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY (2012)
Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial
Hilko Ardon et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Preclinical Evaluation of TriMix and Antigen mRNA-Based Antitumor Therapy
Sandra Van Lint et al.
CANCER RESEARCH (2012)
The secret ally: immunostimulation by anticancer drugs
Lorenzo Galluzzi et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Active Specific Immunotherapy Targeting the Wilms' Tumor Protein 1 (WT1) for Patients with Hematological Malignancies and Solid Tumors: Lessons from Early Clinical Trials
Ann Van Driessche et al.
ONCOLOGIST (2012)
Management of recurrent cervical cancer: A review of the literature
M. Peiretti et al.
SURGICAL ONCOLOGY-OXFORD (2012)
PGE2-Induced CXCL12 Production and CXCR4 Expression Controls the Accumulation of Human MDSCs in Ovarian Cancer Environment
Natasa Obermajer et al.
CANCER RESEARCH (2011)
Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer
Ignace Vergote et al.
EUROPEAN JOURNAL OF CANCER (2011)
Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies
Katayoun Rezvani et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Tumor-infiltrating Cytotoxic T Lymphocytes as Independent Prognostic Factor in Epithelial Ovarian Cancer With Wilms Tumor Protein 1 Overexpression
Renee Vermeij et al.
JOURNAL OF IMMUNOTHERAPY (2011)
Calculator for ovarian carcinoma subtype prediction
Steve E. Kalloger et al.
MODERN PATHOLOGY (2011)
WT1 Immunoprofiling and Comparison of Malignant Mullerian Mixed Tumors of The Female Genital Tract
Angela Franko et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2010)
Primary Ovarian Mucinous Carcinoma of Intestinal Type: Significance of Pattern of Invasion and Immunohistochemical Expression Profile in a Series of 31 Cases
Ali Dastranj Tabrizi et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2010)
Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination
Antonia Busse et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2010)
Identification of the Most Sensitive and Robust Immunohistochemical Markers in Different Categories of Ovarian Sex Cord-stromal Tumors
Chengquan Zhao et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2009)
Cluster Analysis of Immunohistochemical Markers in Leiomyosarcoma Delineates Specific Anatomic and Gender Subgroups
Jason C. Carvalho et al.
CANCER (2009)
Single-Step Antigen Loading and Activation of Dendritic Cells by mRNA Electroporation for the Purpose of Therapeutic Vaccination in Melanoma Patients
Aude Bonehill et al.
CLINICAL CANCER RESEARCH (2009)
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
Martin A. Cheever et al.
CLINICAL CANCER RESEARCH (2009)
WT1, p53 and hormone receptor expression in uterine serous carcinoma
Lynn Hirschowitz et al.
HISTOPATHOLOGY (2009)
Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties
Sebastien Anguille et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2009)
Clinical management of uterine sarcomas
Frederic Amant et al.
LANCET ONCOLOGY (2009)
HPV Vaccination for the Prevention of Cervical Intraepithelial Neoplasia
Jessica A. Kahn
NEW ENGLAND JOURNAL OF MEDICINE (2009)
A Limited Panel of Immunomarkers Can Reliably Distinguish Between Clear Cell and High-grade Serous Carcinoma of the Ovary
Martin Köbel et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2008)
Wilms tumor gene protein 1 is associated with ovarian cancer metastasis and modulates cell invasion
Maria V. Barbolina et al.
CANCER (2008)
Wilms' tumor gene 1 (WT1) in endometrial carcinoma
An Coosemans et al.
GYNECOLOGIC ONCOLOGY (2008)
Immunophenotyping of serous carcinoma of the female genital tract
Sharon Nofech-Mozes et al.
MODERN PATHOLOGY (2008)
WT1 expression in endometrioid ovarian carcinoma with and without associated endometriosis
C. J. R. Stewart et al.
PATHOLOGY (2008)
Cytoplasmic overexpression of WT-1 in gastrointestinal stromal tumor and other soft tissue tumors
Zhanyong Bing et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2008)
Biomarker-assisted diagnosis of ovarian, cervical and pulmonary small cell carcinomas: the role of TTF-1, WT-1 and HPV analysis
J. W. Carlson et al.
HISTOPATHOLOGY (2007)
Diagnostic utility of WT1 immunostaining in ovarian Sertoli cell tumor
Chengquan Zhao et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2007)
Expression level of Wilms tumor 1 (WT1) protein has limited prognostic value in epithelial ovarian cancer - From the Danish MALOVA Ovarian Cancer Study
Estrid V. S. Hogdall et al.
GYNECOLOGIC ONCOLOGY (2007)
Clinicopathological significance of WT1 expression in ovarian cancer: a possible accelerator of tumor progression in serous adenocarcinoma
Sohei Yamamoto et al.
VIRCHOWS ARCHIV (2007)
Upregulation of Wilms' tumour gene 1 (WT1) in uterine sarcomas
A. Coosemans et al.
EUROPEAN JOURNAL OF CANCER (2007)
DC-based cancer vaccines
Eli Gilboa
JOURNAL OF CLINICAL INVESTIGATION (2007)
The many facets of the Wilms' tumour gene, WT1
Peter Hohenstein et al.
HUMAN MOLECULAR GENETICS (2006)
WTI gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study
Wirote Netinatsunthorn et al.
BMC CANCER (2006)
Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer
B Hylander et al.
GYNECOLOGIC ONCOLOGY (2006)
Immunohistochemical characterization of endocervical papillary serous carcinoma
S Nofech-Mozes et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2006)
Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines
A Michiels et al.
GENE THERAPY (2005)
The utility of calretinin, inhibin, and WT1 immunohistochemical staining in the differential diagnosis of ovarian tumors
HP Cathro et al.
HUMAN PATHOLOGY (2005)
Expression of cancer-testis antigens in endometrial carcinomas using a tissue microarray
DA Chitale et al.
MODERN PATHOLOGY (2005)
Differential expression of WT1 and p53 in serous and endometrioid carcinomas of the endometrium
JA Egan et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2004)
WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium
G Acs et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2004)
The Wilms' tumour protein (WT1) shuttles between nucleus and cytoplasm and is present in functional polysomes
M Niksic et al.
HUMAN MOLECULAR GENETICS (2004)
WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma
M Al-Hussaini et al.
HISTOPATHOLOGY (2004)
Wilms tumor gene (WT1) and p53 expression in endometrial carcinomas: a study of 130 cases using a tissue microarray
J Dupont et al.
GYNECOLOGIC ONCOLOGY (2004)
Endometrial stromal neoplasms are immunoreactive with WT-l antibody
VP Sumathi et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2004)
The use of cytokeratin 7 and EMA in differentiating ovarian yolk sac tumors from endometrioid and clear cell carcinomas
P Ramalingam et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2004)
Wilms tumor gene immunoreactivity in primary serous carcinomas of the fallopian tube, ovary, endometrium, and peritoneum
A Hashi et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2003)
Ovarian sex cord-stromal tumors: An immunohistochemical study including a comparison of calretinin and inhibin
MT Deavers et al.
MODERN PATHOLOGY (2003)
Immunoprofile of ovarian tumors with putative transitional cell (urothelial) differentiation using novel urothelial markers - Histogenetic and diagnostic implications
S Logani et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2003)
P53 and Bcl-2 as prognostic predictors in epithelial ovarian cancer
RAM Sagarra et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2002)
Immunohistochemical distinction of endometrial stromal sarcoma and cellular leiomyoma
SN Agoff et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2001)
Share Paper
